Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Buys $465,750.00 in Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi acquired 675,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 25th. The shares were acquired at an average cost of $0.69 per share, for a total transaction of $465,750.00. Following the transaction, the chief executive officer now owns 1,999,296 shares of the company’s stock, valued at approximately $1,379,514.24. This represents a 50.97 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Krishna Vaddi also recently made the following trade(s):

• On Wednesday, March 12th, Krishna Vaddi purchased 47,500 shares of Prelude Therapeutics stock. The shares were acquired at an average price of $0.71 per share, for a total transaction of $33,725.00.
• On Monday, December 30th, Krishna Vaddi acquired 10,000 shares of Prelude Therapeutics stock. The stock was acquired at an average price of $1.20 per share, with a total value of $12,000.00.

Prelude Therapeutics Price Performance

Shares of NASDAQ PRLD traded up $0.04 during trading hours on Thursday, hitting $0.68. 286,920 shares of the stock were exchanged, compared to its average volume of 248,758. The firm has a market capitalization of $37.60 million, a P/E ratio of -0.38 and a beta of 1.43. Prelude Therapeutics Incorporated has a one year low of $0.62 and a one year high of $6.80. The company’s 50 day moving average is $0.90 and its 200 day moving average is $1.35.

Prelude Therapeutics (NASDAQ:PRLD) last issued its quarterly earnings results on Monday, March 10th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.11. The business had revenue of $4.00 million during the quarter. Research analysts anticipate that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year.

Institutional Trading of Prelude Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRLD. XTX Topco Ltd bought a new stake in shares of Prelude Therapeutics in the third quarter valued at approximately $100,000. State Street Corp raised its stake in Prelude Therapeutics by 35.1% during the 3rd quarter. State Street Corp now owns 286,046 shares of the company’s stock valued at $592,000 after purchasing an additional 74,300 shares during the last quarter. Barclays PLC boosted its holdings in Prelude Therapeutics by 86.0% in the 3rd quarter. Barclays PLC now owns 27,165 shares of the company’s stock valued at $57,000 after purchasing an additional 12,564 shares during the period. Geode Capital Management LLC boosted its holdings in Prelude Therapeutics by 8.2% in the 3rd quarter. Geode Capital Management LLC now owns 391,716 shares of the company’s stock valued at $811,000 after purchasing an additional 29,765 shares during the period. Finally, Walleye Capital LLC grew its position in Prelude Therapeutics by 446.2% in the 3rd quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock worth $172,000 after purchasing an additional 67,946 shares during the last quarter. Institutional investors and hedge funds own 79.72% of the company’s stock.

Analyst Ratings Changes

Separately, JMP Securities restated a “market outperform” rating and set a $4.00 target price (down from $7.00) on shares of Prelude Therapeutics in a report on Wednesday, December 11th.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.